Publication: Effects of hydroxychloroquine plus favipiravir treatment on the clinical course and biomarkers in hospitalized covid-19 patients with pneumonia
Loading...
Files
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
SUMMARY – Background: The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia. Unfortunately, the optimal treatment approach is still uncertain. However, many studies have been conducted
on the effectiveness of several medications in the treatment of COVID-19 infection. The aim of this study was
to evaluate the effectiveness of the hydroxychloroquine (HCQ) + favipiravir (FAV) treatment regimen and HCQ
alone by comparing the patient’s clinical response and laboratory results on the fifth day of treatment in patients
hospitalized due to COVID-19 infection.
Patients and methods: This retrospective cohort study was conducted in Malatya Training and Research Hospital
between March 2020 and July 2020. The study included 69 patients with confirmed COVID-19 with pneumonia. The
patients were divided into 2 groups, those receiving HCQ alone and those receiving the HCQ + FAV combination.
Results: A total of 69 patients were included in the study, and the mean age was 60.09±15.56 years. A statistically significant decrease was observed in C-reactive protein (CRP) levels, at the end of the fifth day, in patients who
received HCQ + FAV treatment (p=0.002), whereas there was no decrease in CRP levels in patients who received
HCQ treatment alone. In addition, an increase in lymphocyte count and a better fever response was observed at the
end of the fifth day in patients who received HCQ + FAV (p=0.008). However, there was no statistical difference
between both treatment regimens in terms of hospital stay and treatment results (p=0.008, p=0.744, p=0.517).
Conclusion: Although the combination of HCQ + FAV treatment was observed to be effective on CRP levels and
fever response in patients with COVID-19 pneumonia, there was no difference in terms of hospital stay and discharge.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, Göğüs Hastalıkları ve Allerji, İç Hastalıkları, Yoğun Bakım, Sağlık Bilimleri, Medicine, Internal Medicine Sciences, Chest Diseases and Allergy, Internal Diseases, Intensive Care, Health Sciences, Klinik Tıp (MED), Klinik Tıp, SOLUNUM SİSTEMİ, YOĞUN BAKIM, TIP, GENEL & DAHİLİ, Clinical Medicine (MED), CLINICAL MEDICINE, RESPIRATORY SYSTEM, CRITICAL CARE MEDICINE, MEDICINE, GENERAL & INTERNAL, Solunum Bakımı, Genel Sağlık Meslekleri, Patofizyoloji, Temel Bilgi ve Beceriler, Değerlendirme ve Teşhis, Akciğer ve Solunum Tıbbı, Dahiliye, Aile Sağlığı, Yoğun Bakım Tıbbı, Tıp (çeşitli), Genel Tıp, Respiratory Care, General Health Professions, Pathophysiology, Fundamentals and Skills, Assessment and Diagnosis, Pulmonary and Respiratory Medicine, Internal Medicine, Family Practice, Critical Care and Intensive Care Medicine, Medicine (miscellaneous), General Medicine, Favipiravir, hydroxychloroquine, COVID-19, SARS-COV-2, pneumonia
Citation
Acun Delen L., Gök A., Kasapoğlu U. S., Çağaşar Ö., Ekici Gök Z., Berber N., Derya S., Tetik B., "Effects of Hydroxychloroquine Plus Favipiravir Treatment on the Clinical Course and Biomarkers in Hospitalized COVID-19 Patients with Pneumonia", ACTA CLINICA CROATICA, cilt.61, sa.3, ss.403-411, 2022